Sera Prognostics Inc

NASDAQ SERA

Data sourced from

and

Download Data

Sera Prognostics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2023: 0.29

Sera Prognostics Inc Accounts Payable Turnover Ratio is 0.29 for the year ending December 31, 2023, a 68.98% change year over year. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues.

Sera Prognostics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2022 was 0.17, a 152.72% change year over year.
Sera Prognostics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2021 was 0.07, a 20.84% change year over year.
Sera Prognostics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2020 was 0.06, a 17.79% change year over year.
Sera Prognostics Inc Accounts Payable Turnover Ratio for the year ending December 31, 2019 was 0.05.

NASDAQ: SERA

Sera Prognostics Inc

CEO	Dr. Gregory C. Critchfield M.D., M.S.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees	55
Sector	Healthcare
Industry	Diagnostics & research

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends